The DPP-4 inhibitor-induced glomerular lesions we reported are similar to the glomerular lesions reported by Eremina et al. as VEGF inhibitor-induced thrombotic microangiopathy [9]. This evidence concerns the gene VEGFA and Genetic thrombotic microangiopathy.